|
Feb 22
|
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
|
|
Feb 20
|
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Jan 18
|
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
|
|
Jan 12
|
How Argenx (ARGX) Stock Stands Out in a Strong Industry
|
|
Jan 2
|
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 22
|
UPDATE 2-European shares end slightly higher ahead of Christmas holiday
|
|
Dec 21
|
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
|
|
Dec 21
|
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
|
|
Dec 20
|
Stock Market Does Sharp About-Face; Dow Breaks Win Streak
|
|
Dec 20
|
Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart
|
|
Dec 20
|
Argenx autoimmune drug study fails in blow to expansion hopes
|
|
Dec 20
|
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
|
|
Dec 18
|
argenx SE’s (ARGX) Share Price Increased By 28% Due to Several Factors
|
|
Dec 8
|
Why is Argenx (ARGX) a Suitable Investment Option?
|
|
Dec 3
|
12 Stocks Billionaire Steve Cohen Just Bought and Sold
|
|
Dec 1
|
Several Catalysts Pushed argenx SE (ARGX) in Q3
|
|
Nov 28
|
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
|
|
Nov 28
|
These 2 Stocks Are Falling in a Fading Rally
|
|
Nov 28
|
UPDATE 2-November rally in European stocks stalls after comments from ECB officials
|
|
Nov 28
|
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
|